SCHEMBL5159804

SCHEMBL5159804

CNC(=O)CC(=O)c1cncnc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.45
PLOD2 O00469 3/20 0.38
ALDH1A1 P00352 4/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 2/20 0.35
BCAT2 O15382 1/20 0.34
PLOD3 O60568 2/20 0.34
PLOD1 Q02809 2/20 0.34
ATM Q13315 2/20 0.33
CYP3A4 P08684 2/20 0.33
HPGD P15428 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164294 0.81 HCAR2 (0.42) HCAR2PLOD2ALDH1A1L3MBTL1HDAC1
SCHEMBL5162475 0.78 PLOD2 (0.67) HCAR2PLOD2ALDH1A1L3MBTL1PLOD3
SCHEMBL4638485 0.76 HCAR2 (0.45) HCAR2PLOD2ALDH1A1KDM4EBCAT2
SCHEMBL5160670 0.76 PLOD2 (0.60) PLOD2ALDH1A1L3MBTL1KDM4EPLOD3
SCHEMBL5163325 0.75 HCAR2 (0.48) HCAR2PLOD2ALDH1A1L3MBTL1KDM4E
SCHEMBL5157970 0.74 HCAR2 (0.43) HCAR2PLOD2ALDH1A1KDM4EBCAT2
SCHEMBL6249575 0.74 HCAR2 (0.52) HCAR2PLOD2L3MBTL1KDM4EBCAT2
SCHEMBL669122 0.74 HCAR2 (0.58) HCAR2ALDH1A1KDM4EBCAT2HPGD
SCHEMBL1484349 0.73 CYP1A2 (0.41) HCAR2CYP3A4CYP1A2CYP2C9RAB9A
SCHEMBL6274915 0.73 HCAR2 (0.52) HCAR2PLOD2ALDH1A1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO HCAR2 12/4885PLOD2 1169/4885ALDH1A1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.